Miltefosine Plus IL Pentamidine for Bolivian CL

• Status: Completed
• Trial end date: 2018-02-21
• Target enrollment: 0
• Participant gender: All

Summary

Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jonathan Berman
• Treatments: Miltefosine; Pentamidine

Criteria

Inclusion Criteria:

• one ulcerative lesion ≤ 900 mm2 in total area,

• ≥ 12 years,

• parasitologically diagnosed by visualization of amastigotes or culture of promastigotes from lesion material,

• no antileishmanial therapy in the last 3 months,

• no mucosal lesions,

• no history of significant concomitant diseases including immunosuppression.

Exclusion Criteria: